Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Location Directory

Clinical trials in Durham, North Carolina

This page shows live ClinicalTrials.gov search results for Durham, North Carolina, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 6:08 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1195
Shown on this page
12
Current sort
Recently updated
Location scope
Durham, NC
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Durham, North Carolina. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 337–348 of 1,195 matching trials in Durham, NC.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Institutions in Durham

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Live official records

Open in full search
Active, not recruiting No phase listed Observational

Long-Term Outcomes After the Multisystem Inflammatory Syndrome in Children

NCT05287412
View directory record Official record
Conditions
Multisystem Inflammatory Syndrome in Children (MIS-C)
Interventions
Not listed
Lead sponsor
Carelon Research
Other
Eligibility
Up to 21 Years
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
32
States / cities
Tuscaloosa, Alabama • Phoenix, Arizona • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Nov 6, 2026, 6:08 AM EST
Active, not recruiting Phase 3 Interventional

Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT04095364
View directory record Official record
Conditions
Low Grade Fallopian Tube Serous Adenocarcinoma, Ovarian Low Grade Serous Adenocarcinoma, Primary Peritoneal Low Grade Serous Adenocarcinoma, Stage II Fallopian Tube Cancer AJCC v8, Stage II Ovarian Cancer AJCC v8, Stage II Primary Peritoneal Cancer AJCC v8, Stage III Fallopian Tube Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Carboplatin, Imaging Procedure, Letrozole, Paclitaxel
Procedure · Drug
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
883
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Goodyear, Arizona + 562 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Nov 6, 2026, 6:08 AM EST
Recruiting Phase 1Phase 2 Interventional

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

NCT04988555
View directory record Official record
Conditions
Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute, Multiple Myeloma, Myelodysplastic Syndromes
Interventions
Enzomenib, azoles, Venetoclax, Gilteritinib, Azacitidine (AZA), Intensive chemotherapy with 7 + 3
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
33
States / cities
Newport Beach, California • Palo Alto, California • Denver, Colorado + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Nov 6, 2026, 6:08 AM EST
Terminated Phase 1Phase 2 Interventional

A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer

NCT03288545
View directory record Official record
Conditions
Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Urologic Neoplasms, Renal Pelvis Neoplasms, Urothelial Cancer, Ureteral Neoplasms, Urethral Neoplasms
Interventions
enfortumab vedotin (EV), pembrolizumab, cisplatin, carboplatin, gemcitabine
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
83
States / cities
Anchorage, Alaska • Gilbert, Arizona • Phoenix, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Nov 6, 2026, 6:08 AM EST
Active, not recruiting Phase 2 Interventional

Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)

NCT04268550
View directory record Official record
Conditions
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Selpercatinib
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Not listed
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
306
States / cities
Fairbanks, Alaska • Little Rock, Arkansas • Anaheim, California + 251 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Nov 6, 2026, 6:08 AM EST
Completed Phase 2 Interventional Results available

Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy

NCT02690558
View directory record Official record
Conditions
Bladder Cancer
Interventions
pembrolizumab, gemcitabine and cisplatin
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Nov 6, 2026, 6:08 AM EST
Active, not recruiting No phase listed Observational

CASCADE-LUNG: Cancer Screening Assay Using DELFI; A Clinical Validation Study in Lung

NCT05306288
View directory record Official record
Conditions
Lung Cancer
Interventions
Blood Sample Collection
Other
Lead sponsor
Delfi Diagnostics Inc.
Industry
Eligibility
50 Years and older
Enrollment
11,935 participants
Timeline
2022 – 2026
U.S. locations
66
States / cities
Cullman, Alabama • Culver City, California • Mission Hills, California + 55 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Nov 6, 2026, 6:08 AM EST
Completed Phase 3 Interventional Results available

S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma

NCT00006721
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, cyclophosphamide, doxorubicin, prednisone, vincristine, tositumomab
Biological · Drug · Radiation
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
571 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2025
U.S. locations
259
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Fort Smith, Arkansas + 167 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Nov 6, 2026, 6:08 AM EST
Active, not recruiting Not applicable Interventional

Casting vs Bracing for Idiopathic Early-Onset Scoliosis

NCT04500041
View directory record Official record
Conditions
Scoliosis Idiopathic, Early-Onset Scoliosis Deformity of Spine
Interventions
Casting, Bracing
Procedure · Device
Lead sponsor
University of Iowa
Other
Eligibility
12 Months to 36 Months
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
24
States / cities
Little Rock, Arkansas • Aurora, Colorado • Wilmington, Delaware + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Nov 6, 2026, 6:08 AM EST
Completed Phase 3 Interventional Results available

Open-label Trial to Check the Safety and Tolerability of RTX-GRT7039 Injections for Pain Associated With Osteoarthritis of the Knee

NCT05377489
View directory record Official record
Conditions
Osteoarthritis
Interventions
RTX-GRT7039
Drug
Lead sponsor
Grünenthal GmbH
Industry
Eligibility
18 Years and older
Enrollment
714 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
27
States / cities
Glendale, Arizona • Phoenix, Arizona • Anaheim, California + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Nov 6, 2026, 6:08 AM EST
Completed Phase 2 Interventional Accepts healthy volunteers

A Study to Learn About How a New Pneumococcal Vaccine Works in Children

NCT06531538
View directory record Official record
Conditions
Pneumococcal Disease
Interventions
PG4, 20-valent pneumococcal conjugate vaccine (20vPnC)
Biological
Lead sponsor
Pfizer
Industry
Eligibility
12 Months to 15 Months
Enrollment
225 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
35
States / cities
Washington D.C., District of Columbia • Miami, Florida • Chamblee, Georgia + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Nov 6, 2026, 6:08 AM EST
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564)

NCT03142334
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Pembrolizumab, Placebo
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
994 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
62
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 52 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Nov 6, 2026, 6:08 AM EST